Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14414 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Ruifang Zheng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Biphenotypic, Acute, Genomics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Mixed phenotype acute leukemia ( MPAL ) often poses challenges in diagnosis and clinical management. This is the first study to assess the lineage/immunophenotype‐genotype association and the significance of AML ‐myelodysplasia‐related changes ( MR , cytogenetic abnormalities and gene mutations, AML ‐ MR ‐ CG ‐Gene) in MPAL classification.
Methods
We conducted a clinicopathologic and genomic evaluation of 25 MPAL cases by the WHO ‐ HEM5 / ICC classification criteria, except for retaining those MPAL cases with AML ‐ MR ‐ CG ‐Gene ( Conditional ‐ MPAL ).
Results
The majority of MPAL cases (22/25, 88%) showed distinct genotypes that overlapped with those of lymphoblastic leukemia ( ALL ) and acute myeloid leukemia ( AML ). The genomic profile of ALL ‐like and AML ‐like was associated with immunophenotypically lymphoid and myeloid lineage predominance, respectively. The lineage/immunophenotype‐genotype association may provide a rationale to develop a lineage‐immunophenotypically/biologically guided therapy selection. Additionally, 64% of MPAL cases carried AML ‐ MR ‐ CG ‐Gene, half of which were MPAL with lymphoid‐lineage predominance and had ALL ‐like molecular signatures, and most of these patients responded well to the ALL ‐based induction regimens. These results support that Conditional‐ MPAL with AML ‐ MR ‐ CG ‐Gene may be better diagnosed as MPAL rather than AML ‐ MR .
Conclusion
Genomic landscape of AML‐like or ALL‐like MPAL is associated with the immunophenotypic lineage predominance, and such association could impact treatment decisions and provide supporting evidence to refine MPAL diagnostic criteria in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Internal Medicine (Hematology/Oncology), University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Miguel D Cantu, Yazan F Madanat, Weina Chen
Zitieren
APA
Zheng, R., Gagan, J. R., Botten, G. A., Koduru, P., Weinberg, O. K., Chen, M., Cantu, M. D., Jaso, J., Germans, S., Luu, H. S., Han, L., Slone, T. L., Dickerson, K. E., John, S., Madanat, Y. F., Chung, S., Collins, R., Marinos, A., Fuda, F., & Chen, W. (2025). Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment. European Journal of Haematology. https://doi.org/10.1111/ejh.14414
Vancouver
Zheng R, Gagan JR, Botten GA, Koduru P, Weinberg OK, Chen M, et al. Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment. European Journal of Haematology. 2025. doi:10.1111/ejh.14414
BibTeX
@article{Zheng2025,
author = {Zheng, Ruifang and Gagan, Jeffrey R and Botten, Giovanni A and Koduru, Prasad and Weinberg, Olga K and Chen, Mingyi and Cantu, Miguel D and Jaso, Jesse and Germans, Sharon and Luu, Hung S and Han, Lina and Slone, Tamra L and Dickerson, Kathryn E and John, Samuel and Madanat, Yazan F and Chung, Stephen and Collins, Robert and Marinos, Alejandro and Fuda, Franklin and Chen, Weina},
title = {Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14414}
}
EUVIMED